Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 105 results
October 2022
-
Key ReleaseNovartis maintains growth momentum and confirms FY’22 Group guidanceAd hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc),…
-
Key ReleaseNovartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH studyAd hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…
April 2022
-
Key ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlookAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core…
-
Key ReleaseNovartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivityAd hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation…